Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/978-1-4757-9613-1_19 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Soluble CD26: From Suggested Biomarker for Cancer Diagnosis to Plausible Marker for Dynamic Monitoring of Immunotherapy.
Cancers (Basel)
June 2024
Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.
Soluble CD26 (sCD26), a glycoprotein with dipeptidyl peptidase (DPP4) enzymatic activity, can contribute to early diagnosis of colorectal cancer and advanced adenomas and has been studied, including for prognostic purposes, across various other types of cancer and disease. The latest research in this field has confirmed that most, though not all, serum/plasma sCD26 is related to inflammation. The shedding and/or secretion of sCD26 from different immune cells are being investigated, and blood DPP4 activity levels do not correlate very strongly with protein titers.
View Article and Find Full Text PDFHDAC Inhibition Induces CD26 Expression on Multiple Myeloma Cells via the c-Myc/Sp1-mediated Promoter Activation.
Cancer Res Commun
February 2024
Department of Pathology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
Unlabelled: CD26 is ubiquitously and intensely expressed in osteoclasts in patients with multiple myeloma, whereas its expression in plasma cells of patients with multiple myeloma is heterogeneous because of its cellular diversity, immune escape, and disease progression. Decreased expression levels of CD26 in myeloma cells constitute one of the mechanisms underlying resistance to humanized anti-CD26 mAb therapy in multiple myeloma. In the current study, we show that histone deacetylase inhibition (HDACi) with broad or class-specific inhibitors involves the induction of CD26 expression on CD26neg myeloma cells both transcriptionally and translationally.
View Article and Find Full Text PDFNovel Pharmacological Treatment Options of Steroid-Refractory Graft-versus-Host Disease.
Adv Hematol
December 2023
The Christ Hospital Network, Cincinnati, Ohio, USA.
Article Synopsis
- Graft-versus-host disease (GVHD) is a serious complication of hematopoietic stem cell transplants, with current steroid treatments being ineffective in 30-50% of cases, leading to high mortality rates in steroid-refractory GVHD (SR-GVHD).
- This review analyzes new therapeutic options for SR-GVHD, emphasizing experimental drugs like ruxolitinib, monoclonal antibodies, and other agents that show promise but require more research on their safety and effectiveness.
- While some agents demonstrate potential for improving treatment outcomes in chronic GVHD, further rigorous trials are needed to confirm their efficacy on a larger scale.
Study of Plasma Anti-CD26 Autoantibody Levels in a Cohort of Treatment-Naïve Early Arthritis Patients.
Arch Immunol Ther Exp (Warsz)
March 2022
Rheumatology and Immune-Mediated Diseases Research Group (IRIDIS), Galicia Sur Health Research Institute (IISGS), SERGAS-UVIGO, Vigo, Spain.
Article Synopsis
- Identifying effective biomarkers for early-stage rheumatoid arthritis (RA) remains difficult, highlighting the need for novel markers in diagnosis and treatment adjustment.
- This study investigates the diagnostic potential of autoantibodies (Anti-CD26 aAbs) in 106 treatment-naïve early arthritis patients, revealing different isotype patterns linked to RA and undifferentiated arthritis.
- Findings suggest that Anti-CD26 aAbs may serve as important biomarkers and possible contributors to the disease in both seropositive and seronegative patients, even with weak correlations to traditional disease activity indicators.
Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma.
JTO Clin Res Rep
June 2021
Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
Introduction: YS110, a humanized monoclonal antibody with a high affinity to CD26, exhibited promising antitumor activity and was generally well-tolerated in the phase 1 part of a phase 1 and 2 Japanese trial in patients with malignant pleural mesothelioma (MPM). Here we report the results of the phase 2 part of the study.
Methods: The patients included were aged 20 years and older, had histologically confirmed MPM, were refractory to or intolerant of existing antineoplastic agents, and were not candidates for standard therapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!